"Our goal is to accelerate progress toward a robust set of biomarkers for Parkinson's disease by supporting researchers who have strong leads or innovative approaches, bringing them together, and making it easier for them to share and analyze data across studies," said NINDS director Story Landis, Ph.D.
Nine research teams, listed below, have been funded through the program so far. Four of these projects are associated with the NINDS Udall Centers of Excellence for Parkinson's Disease Research (see projects marked by *).
F. Dubois Bowman, Ph.D., Emory University, Atlanta*
This group will develop statistical tools to analyze data from brain imaging, genetic, molecular and clinical tests, in order to discover biomarkers which, in combination, can better predict the course of Parkinson's disease than a single biomarker might be able to do.
Alice Chen-Plotkin, M.D., Ph.D., University of Pennsylvania, Philadelphia*
This team seeks to confirm several candidate biomarkers they have identified, and search for others by using a novel, broad-ranging approach to measure the levels of more than 400 proteins in blood.
Ted Dawson, M.D., Ph.D., Johns Hopkins University, Baltimore*
This team seeks to gain a clearer picture of the early clinical features of Parkinson's including changes in cognition and sleep and to correlate those changes with potential biomarkers in blood and CSF.
Dwight German, Ph.D., and Richard Dewey, Ph.D., University of Texas Southwestern Medical Center at Dallas
Based on ev
|Contact: Daniel Stimson|
NIH/National Institute of Neurological Disorders and Stroke